These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7102135)

  • 21. Factors affecting calcium oxalate dihydrate fragmented calculi regrowth.
    Costa-Bauzá A; Perelló J; Isern B; Sanchis P; Grases F
    BMC Urol; 2006 Jul; 6():16. PubMed ID: 16822299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium oxalate crystal growth. A new constant composition method for modelling urinary stone formation.
    Sheehan ME; Nancollas GH
    Invest Urol; 1980 May; 17(6):446-50. PubMed ID: 7372431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor.
    Rodgers A; Allie-Hamdulay S; Jackson G
    Nephrol Dial Transplant; 2006 Feb; 21(2):361-9. PubMed ID: 16249202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-molecular-weight dextran sulfate prevents experimental urolithiasis in rats.
    Tostes V; Martinusso CA; Werneck CC; Mourão PA; Cardoso LR
    Clin Chim Acta; 2004 Mar; 341(1-2):147-55. PubMed ID: 14967171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relation of phosphate to formation of calcium oxalate urinary calculi.
    Sun XZ; Zhang YS
    Acta Acad Med Wuhan; 1984; 4(2):100-4. PubMed ID: 6738980
    [No Abstract]   [Full Text] [Related]  

  • 26. Citric acid or citrates in urine: which should we focus on in the prevention of calcium oxalate crystals and stones?
    Laube N; Jansen B; Hesse A
    Urol Res; 2002 Oct; 30(5):336-41. PubMed ID: 12389124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of emergency eye-wash products in burned porcine eyes.
    Kompa S; Schareck B; Tympner J; Wüstemeyer H; Schrage NF
    Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):308-13. PubMed ID: 11981646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Epidemiology of urinary lithiasis in our Unit. Clinical course in time and predictive factors].
    Arias Fúnez F; García Cuerpo E; Lovaco Castellanos F; Escudero Barrilero A; Avila Padilla S; Villar Palasí J
    Arch Esp Urol; 2000 May; 53(4):343-7. PubMed ID: 10900764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allopurinol for calcium oxalate stones?
    Lancet; 1987 Jan; 1(8527):258-9. PubMed ID: 2880074
    [No Abstract]   [Full Text] [Related]  

  • 30. [On the chemolysis of urinary concretions].
    Steyaert M
    Belg Tijdschr Geneesk; 1965 Aug; 21(16):750-8. PubMed ID: 5317914
    [No Abstract]   [Full Text] [Related]  

  • 31. [Report on a symposium on the treatment of Ca-containing urinary calculi using ion exchangers, Munich, May 8, 1976].
    Schmiedt E
    Urologe A; 1976 Sep; 15(5):262. PubMed ID: 973283
    [No Abstract]   [Full Text] [Related]  

  • 32. The nucleation and growth kinetics of calcium oxalate in the presence of some synthetic urine constituents.
    Rodgers AL; Garside J
    Invest Urol; 1981 May; 18(8):484-8. PubMed ID: 7228583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of cellular oxalate in oxalate clearance of patients with calcium oxalate monohydrate stone formation and normal controls.
    Oehlschläger S; Fuessel S; Meye A; Herrmann J; Froehner M; Albrecht S; Wirth MP
    Urology; 2009 Mar; 73(3):480-3. PubMed ID: 19167040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamm-Horsfall glycoprotein and calcium nephrolithiasis.
    Hess B
    Miner Electrolyte Metab; 1994; 20(6):393-8. PubMed ID: 7783702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of osteopontin as matrix protein in calcium-containing urinary stones.
    Yamate T; Umekawa T; Iguchi M; Kurita T; Kohri K
    Hinyokika Kiyo; 1997 Sep; 43(9):623-7. PubMed ID: 9365840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test.
    Voss S; Hesse A; Zimmermann DJ; Sauerbruch T; von Unruh GE
    J Urol; 2006 May; 175(5):1711-5. PubMed ID: 16600737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Detection of urinary organic acids by gradual titration of pH 2,0-7,4. Significance for the assessment of the litho-protective characteristic of the examined urine].
    Leskovar P; Hartung R; Hropot M; Huber H; Friedl H; Wellnhofer E; Steffek D; Schöninger R
    Helv Chir Acta; 1981 Aug; 48(3-4):489-93. PubMed ID: 7287489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new test with [13C2]oxalate.
    Hesse A; Schneeberger W; Engfeld S; Von Unruh GE; Sauerbruch T
    J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S329-33. PubMed ID: 10541257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Calcium oxalate lithiasis. Relationship between biochemical risk factors and crystalline phase of the stone].
    Parent X; Boess G; Brignon P
    Prog Urol; 1999 Dec; 9(6):1051-6. PubMed ID: 10658250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.